Susquehanna International Group, LLP Acadia Pharmaceuticals Inc Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

A detailed history of Susquehanna International Group, LLP transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Susquehanna International Group, LLP holds 329,568 shares of ACAD stock, worth $5.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

329,568

Previous 173,103 90.39%

Holding current value

$5.17 Million

Previous $3.2 Million 67.34%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$14.62 - $18.42 $2.29 Million - $2.88 Million	156,465 Added 90.39%	329,568 $5.36 Million
Q1 2024 May 07, 2024	SELL	$17.79 - $30.86 $3.6 Million - $6.24 Million	-202,160 Reduced 53.87%	173,103 $3.2 Million
Q4 2023 Feb 14, 2024	BUY	$20.78 - $31.77 $1.1 Million - $1.68 Million	52,883 Added 16.4%	375,263 $11.7 Million
Q3 2023 Nov 14, 2023	BUY	$20.84 - $33.47 $5.5 Million - $8.83 Million	263,917 Added 451.43%	322,380 $6.72 Million
Q2 2023 Aug 11, 2023	SELL	$17.8 - $25.65 $3.06 Million - $4.41 Million	-171,797 Reduced 74.61%	58,463 $1.4 Million
Q1 2023 May 16, 2023	BUY	$16.32 - $20.92 $2.47 Million - $3.17 Million	151,522 Added 192.44%	230,260 $4.33 Million
Q4 2022 Feb 14, 2023	SELL	$14.2 - $18.63 $1.6 Million - $2.1 Million	-112,852 Reduced 58.9%	78,738 $1.25 Million
Q3 2022 Nov 14, 2022	BUY	$14.11 - $18.27 $65,992 - $85,448	4,677 Added 2.5%	191,590 $3.13 Million
Q2 2022 Aug 15, 2022	BUY	$13.01 - $27.22 $981,344 - $2.05 Million	75,430 Added 67.66%	186,913 $2.63 Million
Q1 2022 May 16, 2022	SELL	$20.94 - $27.5 $5.88 Million - $7.72 Million	-280,637 Reduced 71.57%	111,483 $2.7 Million
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $1.31 Million - $2.12 Million	78,180 Added 24.9%	392,120 $9.15 Million
Q3 2021 Nov 15, 2021	SELL	$15.78 - $24.77 $3.44 Million - $5.4 Million	-218,034 Reduced 40.99%	313,940 $5.22 Million
Q2 2021 Aug 11, 2021	BUY	$19.4 - $27.42 $5.63 Million - $7.96 Million	290,358 Added 120.17%	531,974 $13 Million
Q1 2021 May 17, 2021	BUY	$25.02 - $54.99 $1.83 Million - $4.01 Million	72,997 Added 43.29%	241,616 $6.23 Million
Q4 2020 Feb 16, 2021	SELL	$41.04 - $56.79 $2.19 Million - $3.03 Million	-53,303 Reduced 24.02%	168,619 $9.01 Million
Q3 2020 Nov 16, 2020	BUY	$36.42 - $57.0 $2.35 Million - $3.68 Million	64,549 Added 41.02%	221,922 $9.15 Million
Q2 2020 Aug 14, 2020	BUY	$39.26 - $52.73 $3.22 Million - $4.32 Million	81,940 Added 108.63%	157,373 $7.63 Million
Q1 2020 May 15, 2020	SELL	$31.65 - $46.87 $7.19 Million - $10.6 Million	-227,086 Reduced 75.07%	75,433 $3.19 Million
Q4 2019 Feb 14, 2020	BUY	$36.21 - $51.4 $1.56 Million - $2.22 Million	43,147 Added 16.64%	302,519 $12.9 Million
Q3 2019 Nov 14, 2019	BUY	$22.22 - $44.01 $1.53 Million - $3.02 Million	68,670 Added 36.01%	259,372 $9.34 Million
Q2 2019 Aug 16, 2019	BUY	$23.32 - $28.12 $309,339 - $373,011	13,265 Added 7.48%	190,702 $5.1 Million
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $2.9 Million - $3.5 Million	124,342 Added 234.19%	177,437 $4.74 Million
Q1 2019 May 15, 2019	SELL	$16.17 - $27.38 $1.2 Million - $2.03 Million	-74,013 Reduced 58.23%	53,095 $1.43 Million
Q4 2018 Feb 14, 2019	SELL	$14.32 - $22.92 $1.97 Million - $3.16 Million	-137,692 Reduced 52.0%	127,108 $2.06 Million
Q1 2018 May 15, 2018	SELL	$22.47 - $32.33 $3.28 Million - $4.72 Million	-145,986 Reduced 35.54%	264,800 $5.95 Million
Q4 2017 Feb 14, 2018	SELL	$26.84 - $39.14 $2.58 Million - $3.76 Million	-96,151 Reduced 18.97%	410,786 $12.4 Million
Q3 2017 Nov 20, 2017	BUY	$29.49 - $38.37 $14.9 Million - $19.5 Million	506,937	506,937 $19.1 Million

Others Institutions Holding ACAD

# of Institutions

288

Shares Held

161M

Call Options Held

723K

Put Options Held

257K

View Full List

About ACADIA PHARMACEUTICALS INC

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.54B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

More about ACAD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Acadia Pharmaceuticals Inc Transaction History